Related Experiment Video
Updated: Mar 1, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
TyG-BMI and risk of CKD progression: Mediation by oxidative stress, fibrosis, and metabolic dysfunction
Bin Zhao1, YunFei Guo1, Yuyang Liu2
1Department of Nephrology, Beijing Haidian Hospital (Haidian Section of Pecking University Third Hospital), Beijing, China.
Abstract:
To investigate the association between the triglyceride-glucose-body mass index (TyG-BMI) and chronic kidney disease (CKD) progression in individuals across the cardiovascular-kidney-metabolic spectrum, and to evaluate the potential mediation by biomarkers of oxidative stress, inflammation, and fibrosis. This study included 9265 adults stratified into cardiovascular-kidney-metabolic stages 0 to 4. Logistic regression and restricted cubic splines assessed the relationship between TyG-BMI and CKD progression. Mediation analysis quantified the indirect effects of the uric acid-to-high-density lipoprotein ratio, fibrosis-4 index, and red cell distribution width-to-albumin ratio. The primary finding of this study is that elevated TyG-BMI significantly increases the risk of chronic kidney disease (CKD) progression. Specifically, for each unit increase in TyG-BMI, the risk of CKD progression rose by 16% (OR = 1.16; 95% CI:1.01-1.30). This association was quantitatively and significantly mediated by the uric acid-to-high-density lipoprotein ratio, the fibrosis-4 index, and the red cell distribution width-to-albumin ratio, indicating the involvement of oxidative, fibrotic, and inflammatory pathways. Our analysis suggests that elevated TyG-BMI may be associated with an increased risk of CKD progression, potentially mediated through oxidative, inflammatory, and fibrotic pathways. These findings warrant further investigation to confirm the potential clinical relevance of TyG-BMI and the implicated pathways.
Related Concept Videos
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease III: Interprofessional Care
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
Chronic Kidney Disease II: Clinical Manifestations
Acute Kidney Injury II: Pathophysiology
Acute Kidney Injury III: Clinical Manifestations

